# Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma

> **NCT07077512** · PHASE2 · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 30 (estimated)

## Conditions studied

- Large B Cell Diffuse Lymphoma
- Mantle Cell Lymphoma (MCL)
- Follicular Lymphoma ( FL)

## Interventions

- **DRUG:** Autoleucel (Relmacabtagene Autoleucel)
- **DRUG:** Sintilimab (PD-1 inhibitor)

## Key facts

- **NCT ID:** NCT07077512
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-15
- **Primary completion:** 2027-01-15
- **Final completion:** 2027-07-15
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-01-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07077512

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07077512, "Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT07077512. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*